JP6839491B2 - 変形性関節症の予防および治療のためのステロイドとゾレドロン酸との併用 - Google Patents

変形性関節症の予防および治療のためのステロイドとゾレドロン酸との併用 Download PDF

Info

Publication number
JP6839491B2
JP6839491B2 JP2015561747A JP2015561747A JP6839491B2 JP 6839491 B2 JP6839491 B2 JP 6839491B2 JP 2015561747 A JP2015561747 A JP 2015561747A JP 2015561747 A JP2015561747 A JP 2015561747A JP 6839491 B2 JP6839491 B2 JP 6839491B2
Authority
JP
Japan
Prior art keywords
zoledronic acid
pharmaceutically acceptable
acceptable salt
osteoarthritis
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015561747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510765A (ja
JP2016510765A5 (enExample
Inventor
デサイ，ケタン
Original Assignee
レボルタ ファーマシューティカルズ，インコーポレイテッド
レボルタ ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レボルタ ファーマシューティカルズ，インコーポレイテッド, レボルタ ファーマシューティカルズ，インコーポレイテッド filed Critical レボルタ ファーマシューティカルズ，インコーポレイテッド
Publication of JP2016510765A publication Critical patent/JP2016510765A/ja
Publication of JP2016510765A5 publication Critical patent/JP2016510765A5/ja
Application granted granted Critical
Publication of JP6839491B2 publication Critical patent/JP6839491B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
JP2015561747A 2013-03-08 2014-03-07 変形性関節症の予防および治療のためのステロイドとゾレドロン酸との併用 Expired - Fee Related JP6839491B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/791,685 US9012432B2 (en) 2013-03-08 2013-03-08 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US13/791,685 2013-03-08
PCT/US2014/022169 WO2014138712A1 (en) 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019071500A Division JP2019104762A (ja) 2013-03-08 2019-04-03 変形性関節症の予防および治療のためのステロイドとゾレドロン酸との併用

Publications (3)

Publication Number Publication Date
JP2016510765A JP2016510765A (ja) 2016-04-11
JP2016510765A5 JP2016510765A5 (enExample) 2017-04-06
JP6839491B2 true JP6839491B2 (ja) 2021-03-17

Family

ID=51488530

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015561747A Expired - Fee Related JP6839491B2 (ja) 2013-03-08 2014-03-07 変形性関節症の予防および治療のためのステロイドとゾレドロン酸との併用
JP2019071500A Pending JP2019104762A (ja) 2013-03-08 2019-04-03 変形性関節症の予防および治療のためのステロイドとゾレドロン酸との併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019071500A Pending JP2019104762A (ja) 2013-03-08 2019-04-03 変形性関節症の予防および治療のためのステロイドとゾレドロン酸との併用

Country Status (12)

Country Link
US (1) US9012432B2 (enExample)
EP (1) EP2964209B1 (enExample)
JP (2) JP6839491B2 (enExample)
KR (1) KR102253394B1 (enExample)
CN (1) CN105324113B (enExample)
AU (1) AU2014225373B2 (enExample)
BR (1) BR112015021503B1 (enExample)
CA (1) CA2941346C (enExample)
EA (1) EA032067B1 (enExample)
ES (1) ES2904365T3 (enExample)
MX (1) MX377447B (enExample)
WO (1) WO2014138712A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017155233A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913772B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
US10913771B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
WO2017155234A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
KR101897122B1 (ko) 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
JP7127616B2 (ja) 2019-06-04 2022-08-30 横河電機株式会社 情報処理装置、アラーム管理システム、及びアラーム管理方法
WO2021163432A1 (en) * 2020-02-12 2021-08-19 Levolta Pharmaceuticals, Inc. Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275821B1 (de) 1986-11-21 1992-02-26 Ciba-Geigy Ag Neue substituierte Alkandiphosphonsäuren
US7018647B1 (en) * 1999-12-27 2006-03-28 Teikoku Seiyaku Co., Ltd Patches for external use
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2449934A1 (en) * 2001-06-08 2002-12-19 Ortho-Mcneil Pharmaceutical, Inc. Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
MXPA06003063A (es) * 2003-09-19 2006-05-31 Pfizer Prod Inc Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina- d y un bisfosfonato.
EP1758653A2 (en) * 2004-06-17 2007-03-07 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
JP5240925B2 (ja) * 2005-05-25 2013-07-17 カロシン ファーマ， インコーポレイテッド 変形性関節症を処置するための方法および組成物
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
MX2009001248A (es) * 2006-08-03 2009-02-11 Nitec Pharma Ag Tratamiento con glucocorticoide de liberacion prolongada de enfermedad reumatoide.
WO2010071866A2 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
JP5648174B2 (ja) * 2009-05-04 2015-01-07 ヌボ リサーチ インコーポレイテッド 神経腫、神経絞扼、および他の状態と関連する疼痛を処置する方法
US8946199B2 (en) 2010-04-26 2015-02-03 Ketan Desai Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion

Also Published As

Publication number Publication date
WO2014138712A1 (en) 2014-09-12
MX377447B (es) 2025-03-10
BR112015021503B1 (pt) 2022-09-06
MX2015011671A (es) 2016-05-12
KR102253394B1 (ko) 2021-05-20
ES2904365T3 (es) 2022-04-04
JP2016510765A (ja) 2016-04-11
US20140256681A1 (en) 2014-09-11
AU2014225373B2 (en) 2018-07-05
CA2941346A1 (en) 2014-09-12
AU2014225373A1 (en) 2015-10-22
EP2964209B1 (en) 2021-10-27
US9012432B2 (en) 2015-04-21
CN105324113A (zh) 2016-02-10
BR112015021503A2 (pt) 2018-05-15
EP2964209A1 (en) 2016-01-13
EP2964209A4 (en) 2016-08-03
JP2019104762A (ja) 2019-06-27
CA2941346C (en) 2020-03-10
CN105324113B (zh) 2018-07-03
EA032067B1 (ru) 2019-04-30
KR20150125001A (ko) 2015-11-06
EA201591638A1 (ru) 2016-02-29

Similar Documents

Publication Publication Date Title
US9737553B2 (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
JP6839491B2 (ja) 変形性関節症の予防および治療のためのステロイドとゾレドロン酸との併用
US20250295869A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
Mazumder et al. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice
JP6656484B2 (ja) 放射性抗腫瘍剤
WO2021163432A1 (en) Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
US20060217425A1 (en) Methods of treating cancer using PPAR-gamma antagonists
US20250177352A1 (en) Combination treatment for cancer
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
RU2816126C2 (ru) Способ лечения злокачественной опухоли
JP6457555B2 (ja) 疼痛用破骨細胞インヒビター
KR20170138405A (ko) 다발성 골수종의 로네파르스탯트 병행 치료
AU2011279391A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
CA2950443A1 (en) Osteoclast inhibitors for pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190403

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190404

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190424

C12 Written invitation by the commissioner to file intermediate amendments

Free format text: JAPANESE INTERMEDIATE CODE: C12

Effective date: 20190424

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190611

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190612

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190809

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190814

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200304

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200408

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201116

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210107

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210203

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210215

R150 Certificate of patent or registration of utility model

Ref document number: 6839491

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees